NMN (Nicotinamide Mononucleotide) for Healthy Ageing
TL;DR
NAD+ levels decline with age. NMN is a direct precursor that human trials show can raise blood NAD+ and may support functional markers such as walking speed and sleep quality in older adults. Evidence is promising for supporting cellular energy and healthy ageing processes, though large long-term trials with broad healthspan endpoints are still limited. Evidence rating: ⭐⭐⭐ Promising.
Evidence Rating: ⭐⭐⭐ Promising (reliable NAD+ elevation + supportive functional signals in older adults; limited pure longevity endpoint data)
What the Research Shows for Healthy Ageing
NAD+ is central to mitochondrial energy production, DNA repair, and cellular resilience. Its levels fall with chronological age. NMN provides a substrate for NAD+ synthesis. Randomised trials in older adults have demonstrated that daily oral NMN increases circulating NAD+ and its metabolites. Secondary outcomes in several studies include maintained or improved walking speed and better sleep quality scores — both relevant to functional independence with age.
Key Benefits
- Reliably raises blood NAD+ levels in older adults
- May help maintain walking speed (a key marker of functional capacity)
- May support sleep quality in older adults
- Supports cellular energy pathways that decline with age
- Generally well tolerated at studied doses
Key Studies
- Igarashi M. et al. (2022) — RCT in healthy older men. 250 mg/day NMN for 12 weeks significantly increased blood NAD+ and showed nominal improvements in gait speed and grip strength. npj Aging. DOI: 10.1038/s41514-022-00084-z
- Morifuji M. et al. (2024) — RCT in older adults. 250 mg/day for 12 weeks raised NAD+, maintained walking speed and improved sleep quality scores. GeroScience, 46(5), 4671–4688. DOI: 10.1007/s11357-024-01204-1
- Yi L. et al. (2023) — Dose-dependent trial in middle-aged adults showing improved six-minute walk distance at higher doses alongside NAD+ elevation. GeroScience. DOI: 10.1007/s11357-022-00705-1
Expert Views
Dr. David Sinclair has extensively researched NAD+ biology and ageing. Human trials with NMN are translating aspects of that work into measurable biomarker and functional outcomes.
Dr. Peter Attia discusses NAD+ precursors with measured optimism, noting the strong mechanistic case while highlighting the need for more robust long-term human data.
NZ Context for Healthy Ageing
New Zealand’s ageing population places increasing value on maintaining mobility, energy and independence. NMN is one of the nutrients some Kiwis explore as part of a broader healthy-ageing approach that includes resistance training, sleep, protein intake and medical care.
Recommended Dosage for Healthy Ageing
- Commonly studied dose in older adults: 250 mg per day
- Some trials used 300–900 mg with additional functional signals
- Take consistently; morning dosing is typical
- Best viewed as one component of a comprehensive healthy-ageing strategy
Safety Notes
NMN has been well tolerated in trials lasting up to 12–24 weeks. Long-term safety data are still accumulating. Consult your doctor before starting, particularly if you have existing medical conditions.
This is not medical advice. BioHackNZ provides general information based on published research. NMN is a complementary supplement and is not intended to diagnose, treat, cure, or prevent any disease. Always consult your healthcare provider before starting any supplement regimen. Individual results vary.
Last updated: 22 August 2026 | BioHackNZ Research Team
Shop Nicotinamide Mononucleotide (NMN)
View Product →